Please ensure Javascript is enabled for purposes of website accessibility

Elan Investors Receive Royal Treatment

By Dave Williamson - Apr 15, 2013 at 6:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Elan's sweet new royalties deal.

In the following video, Motley Fool health-care analyst David Williamson discusses Elan's (ELN) sale of the rights to its MS treatment drug Tysabri to Biogen Idec (BIIB -3.54%) for $3.25 billion. This leaves Elan not only with a huge pile of cash and a nice revenue stream coming from the royalties of sales of the drug, but it has also drawn the interest of the privately held firm Royalty Pharma, which specializes in acquiring companies with intellectual-property revenue streams. David tells us what this could mean for Elan investors as a possible M&A deal could be getting closer, and what we will need to watch for from Elan, to know whether Royalty will remain interested.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elan Corporation Limited Stock Quote
Elan Corporation Limited
Biogen Inc. Stock Quote
Biogen Inc.
$195.71 (-3.54%) $-7.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.